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Abstract: Marine algae contain various bromophenols that have been shown to possess a 
variety of biological activities, including antioxidant, antimicrobial, anticancer, anti-diabetic, 
and anti-thrombotic effects. Here, we briefly review the recent progress of these marine algal 
biomaterials, with respect to structure, bioactivities, and their potential application   
as pharmaceuticals. 
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1. Introduction  
Marine algae are one of the richest sources of structurally diverse natural products. In recent years, an 
increasing number of novel compounds have been isolated from marine algae and many of them have 
been reported to possess interesting biological activities [1–3]. One kind of these marine algae derived 
compounds is the bromophenols (BPs). BPs share one or several benzene rings, a varying degree of 
bromine and hydroxyl-substituents (see schemes). The first two marine BPs were isolated from the red 
algae Rhodomela larix [4] and thereafter, many novel BPs were isolated and identified from diverse 
species of marine algae, including red algae [4–33], brown algae [34–39], and green algae [40–48].  
It seems that species collected at low tide have a higher content of simple BPs [49]. Some, but not all, 
species of red algae have a relative higher content of certain BPs [49], which may possibly explain 
why so many BPs have been reported from red algae. The BPs were also found to exist in other lower 
marine organisms such as ascidians [50–52] and sponges [53–62]. BPs are common marine secondary 
metabolites, and biosynthesized in the presence of bromoperoxidases, hydrogen peroxide, and 
bromide  [63,64]. The concentration of bromide is about 0.65 mg/kg in seawater and in marine 
algae [49]. The ecological function of BPs is not yet clear, but some of them may play a role in chemical 
defense and deterrence [65]. Recent studies revealed that the marine BPs exhibit a wide spectrum of 
beneficial biological activities [7,10,16,21,25,26,66–70], and therefore these novel BPs have attracted 
much attention in the field of functional food and pharmaceutical agents. In this mini-review, we focus 
on BPs from marine algae and present an overview of their bioactivities and potential application in 
pharmaceutics, since there are only a few reviews in this area [71]. 
2. Bioactivities of BPs and Potential Use in Medicine 
2.1. Antioxidant Activity 
Free radicals attack macromolecules (e.g., membrane lipids, proteins, enzymes, DNA, and RNA) 
and play a pivotal role in several health disorders such as cancer, diabetes, neurodegenerative and 
inflammatory diseases. Therefore, antioxidants may have a beneficial effect on human health by 
preventing free radical damage. 
A growing body of results indicates that BPs have potential antioxidant activity, mainly determined 
by the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging method. For example, BPs 1.1–1.11 
(see Scheme 1) isolated from the red algae Symphyocladia latiuscula, were reported to possess DPPH 
radical scavenging activities [20,21]. All of these BPs are fully substituted by different groups and 
highly brominated, and many of them have a 3,4-dihydroxy-2,5,6-tribromobenzyloxy unit in the 
molecule. These BPs all show scavenging activity towards DPPH radical. Compound 1.2 has the  
highest activity, while compound 1.11 shows the lowest, with IC50 values of 7.5 and 24.7 µM, 
respectively [20,21]. Thus both are more potent than the positive control butylated hydroxytoluene  
(IC50 = 81.8 µM) (see also Table 1). It seems that their antioxidant activity may have a close  
connection to the number of hydroxyl groups in the molecule  [21]. Moreover, their common 
3,4-dihydroxy-2,5,6-tribromobenzyloxy unit or derivatives thereof (see Figure 1) may be another 
important factor for their activity. Mar. Drugs 2011, 9  
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Scheme 1. BPs with antioxidant activity. 
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Table 1. IC50 of the DPPH scavenging activity and names of compounds in Scheme 1. 
No. IC50 (µM)  Names 
1.1  8.5 (2R)-2-(2,3,6-tribromo-4,5-dihydroxybenzyl)-cyclohexanone [20] 
1.2  7.5 2,3,6-tribromo-4,5-dihydroxybenzylalcohol  [20] 
1.3  18.5 1-(2,3,6-tribromo-4,5-dihydroxybenzyl)pyrrolidin-2-one [21] 
1.4  24 2,3,6-tribromo-4,5-dihydroxybenzyl methyl sulfone [21] 
1.5  10.2 1,2-bis(2,3,6-tribromo-4,5-dihydroxyphenyl)ethane  [21] 
1.6  10.5 6-(2,3,6-tribromo-4,5-dihydroxybenzyl)-2,5-dibromo-3,4- 
dihydroxybenzyl methyl ether [21] 
1.7  8.1 Bis(2,3,6-tribromo-4,5-dihydroxyphenyl)methane  [21] 
1.8  8.5 Bis(2,3,6-tribromo-4,5-dihydroxybenzyl)ether  [21] 
1.9  15.5 2,3,6-tribromo-4,5-dihydroxybenzyl methyl ether [21] 
1.10  14.0 2,3,6-tribromo-4,5-dihydroxymethylbenzene  [21] 
1.11  24.7 2,3,6-tribromo-4,5-dihydroxybenzaldehyde  [21] 
1.12  21.9 ± 0.1  3-(3-bromo-4,5-dihydroxyphenyl)-2-(3,5-dibromo-4-hydroxyphenyl) 
propionic acid [25] 
1.13  9.67 ± 0.04  (E)-4-(3-bromo-4,5-dihydroxyphenyl)-but-3-en-2-one [25] 
1.14  16.11 ± 0.06  (3,5-dibromo-4-hydroxyphenyl) acetic acid butyl ester [25] 
1.15  19.64 ± 0.09  1,2-bis(3-bromo-4,5-dihydroxyphenyl)ethane [25] 
1.16  20.3 3-bromo-4,5-dihydroxybenzaldehyde  [26] 
1.17  35.8 3,5-dibromo-4-hydroxybenzaldehyde  [26] 
1.18  6.8 7-bromo-9,10-dihydrophenanthrene-2,3,5,6-tetraol [26] 
1.19  6.1 4,7-dibromo-9,10-dihydrophenanthrene-2,3,5,6-tetraol [26] 
1.20  8.1 1,8-dibromo-5,7-dihydrodibenzo[c,e]oxepine-2,3,9,10-tetraol [26] 
1.21  15.1 Urceolatol  [26] 
1.22  96.2 2,6-dibromo-3,3′,4,4′,5-pentahydroxydiphenylmethanone [72] 
1.23  87.3 2,6-dichloro-3,3′,4,4′,5-pentahydroxydiphenylmethanone [72] 
Figure 1. 3,4-dihydroxy-2,5,6-tribromobenzyloxy unit. 
 
A series of BPs isolated from the red algae Polysiphonia urceolata also exhibit significant 
antioxidant activity. These BPs (1.12–1.21, Scheme 1), are substituted to different degrees and all of 
them show scavenging activity towards DPPH radical. Compounds 1.18 and 1.19, which both have four 
hydroxyl groups in the molecules, are the most active, with IC50 values of 6.8 and 6.1 µM, respectively. 
In contrast, compound 1.17, which only has one hydroxyl substituent in the molecule, is the least active 
with an IC50 of 35.8 µM [25,26]. Therefore, this further supports the idea that the number of hydroxyl 
groups in the molecules plays a vital role for the antioxidant activity. Another important factor is 
conjugation (in the chemical sense) as seen by comparison of 1.19 with 1.15. The former has conjugation Mar. Drugs 2011, 9  
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in the dihydrophenanthrene skeleton. Conjugation effects can of course also be achieved by substituents 
like nitro, acetyl or aldehyde groups in para-position to the OH-group.  
By comparing the IC50 of 1.5 and 1.15, also 1.18 and 1.19, it seems that bromination is not a 
determining factor. Bromination decreases the activity slightly in the case of 1.5 and 1.15, whereas 
bromination increased it slightly for 1.19 vs. 1.18. In another comparison between the natural BPs and 
their corresponding debrominated compounds, it was found that bromination also lead to a decrease in 
the antioxidant activity [73]. Therefore, bromination in the present BPs seems of little importance for 
their antioxidant activity. Recently, Li et al. have investigated some synthetic BPs (1.22), but they have 
only little activity [72]. However, 1.22 and 1.23 allow a comparison between bromine and chlorine 
substitution. Brominations lead to slightly more active compounds. A number of chlorinated compounds 
as well as reference compounds, compounds without halogens, have also been investigated [74]. It is 
obvious that the 1,4 dihydroxy arrangement is very suitable for antioxidant activity. 
Up to now, about 30 BPs from marine algae were reported to have antioxidant activity in vitro. 
However, no in vivo antioxidant studies on marine BPs and their activity have been reported, and 
discussions on the structure and activity relationship (SAR) about BPs are sporadic  [21,26,72,73]. 
Nevertheless, recent studies reveal BPs to be one of the potential candidates in the prevention of 
diseases related to free radical attack, such as cancer, diabetes, neurodegeneration, and inflammation. 
2.2. Anticancer Activity 
Chemotherapy is one of the major therapeutic approaches for cancer treatment, and several 
naturally obtained anticancer drugs, such as camptothecin and taxol, are used clinically [75].  It is 
believed that it is a promising strategy to screen naturally occurring compounds in order to discover 
novel anticancer agents. Several studies have reported that the marine BPs could inhibit the 
proliferation of a number of cancer cell lines in vitro and the growth of tumors in vivo. For example, 
BPs derivatives isolated from the brown algae Leathesia nana, 2.1–2.6 (Scheme 2), which also share 
the 2,3-dibromo-4,5-dihydroxybenzyl unit, are cytotoxic against a variety of human cancer cell lines 
(Table 2), including A549, BGC823, MCF-7, BEL-7402, HCT-8 [35,76]. The Leathesia nana extract, 
rich in BPs, could inhibit the growth of Sarcoma 180 tumors in vivo and improve the immune system 
remarkably [76], indicating its potential use in cancer treatment. 
BPs with cytotoxic activities from the red algae and green algae are structurally simpler than those 
from the brown algae and most of them contain one benzene ring. 3-bromo-4,5-dihydroxy benzoic acid 
methyl ester (2.7) and 3-bromo-4,5-dihydroxy-benzaldehyde (2.8), isolated from marine red algae 
Rhodomela confervoides, are selectively cytotoxic against KB, Bel-7402, and A549 cells (IC50 ranging 
from 3.09 to 8.71 µg/mL (12.5–40.1 µM) [33], while lanosol butenone (2.9), isolated from the New 
Zealand marine red algae Osmundaria colensoi, is cytotoxic against human leukemia cells with an IC50 
value of 8.0 µM [67]. Another compound similar to 2.7 and 2.8, 3-bromo-4,5-dihydroxybenzylalcohol 
(2.10), which was isolated from the tropical green algae Avrainvillea nigricans, was reported to be 
cytotoxic to KB cells with IC50 = 8.9 µg/mL (47 µM) [45]. Mar. Drugs 2011, 9  
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Scheme 2. BPs with anticancer activity. 
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Table 2. Anticancer activity and names of compounds in Scheme 2. 
No. IC50 and cells  Names  
2.1  2.5 (A549), 8.8 (BGC823) 
2.7 (MCF-7), 4.8 (Bel7402) 
16.8 (HCT-8) 
6-(2,3-dibromo-4,5-dihydroxybenzyl)-2,3-dibromo-4,5- 
dihydroxy benzyl methyl ether [35] 
2.2  1.8 (A549), 3.8 (BGC823) 
2.7 (MCF-7), 2.2 (HCT-8) 
>18.2 (Bel7402) 
2,2′,3,3′-tetrabromo-4,4′,5,5′-tetrahydroxydiphenyl- 
methane [35] 
2.3  8.27 (MCF-7) 
6.36 (HT-1080), µg/mL 
(+)-3-(2,3-dibromo-4,5-dihydroxyphenyl)-4-bromo-5,6- 
dihydroxy-1,3-dihydroisobenzofuran [76] 
2.4  >19 (A549), 4.6 (BGC823) 
3.4 (MCF-7), 5.5 (Bel7402) 
2.8 (HCT-8) 
2,2′,3-tribromo-3′,4,4′,5-tetrahydroxy-6′-ethyloxy- 
methyldiphenylmethane [35] 
2.5  >19.5 (A549), 8.6 (BGC823) 
21.4 (MCF-7), 20.7 (HCT-8) 
>1.9 (Bel7402) 
3-bromo-4-(2,3-dibromo-4,5-dihydroxybenzyl)-5- 
methoxymethylpyrocatechol [35] 
2.6  5.4 (A549), 18 (BGC823) 
4.6 (MCF-7), 7.4 (Bel7402) 
5.9 (HCT-8) 
Bis(2,3-dibromo-4,5-dihydroxybenzyl)ether [35] 
2.7  3.09 (KB), 3.18 (Bel-7402) 
3.54 (A549), µg/mL 
3-bromo-4,5-dihydroxybenzoic acid methyl ester [33] Mar. Drugs 2011, 9  
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Table 2. Cont. 
2.8  8.71 (KB), 5.36 (Bel-7402) 
7.56 (A549), µg/mL 
3-bromo-4,5-dihydroxybenzaldehyde [33] 
2.9  8.0 (HL-60)  Lanosol butenone [67] 
2.10  47 (KB)  3-bromo-4,5-dihydroxybenzylalcohol [45] 
2.11  14.6 ± 3.1 (DLD-1) 
14.1 ± 2.5 (HCT116) 
Lanosol methyl ether [69] 
2.12  13.5 ± 2.3 (DLD-1) 
2.51 ± 0.95 (HCT116) 
Lanosol ethyl ether [69] 
2.13  12.4 ± 1.1 (DLD-1) 
1.32 ± 0.3 (HCT116) 
Lanosol n-propyl ether [69] 
2.14  1.72 ± 0.29 (DLD-1) 
0.8 ± 0.63 (HCT116) 
2,5-dibromo-3,4-dihydroxybenzyl n-propyl ether [69] 
2.15  19.7 (A549), 19.9 (A2780) 
19.4 (Bel-7402), 15.4 (HCT-8) 
20.2 (BGC-823) 
2,3-dibromo-4,5-dihydroxyphenylethanol [16] 
2.16  14.7 (A549), 9.4 (A2780) 
14.8 (Bel-7402), 14.0 (BGC-823)
14.6 (HCT-8) 
2,3-dibromo-4,5-dihydroxyphenylethanol sulfate [16] 
2.17  18.5 (A549), 20.8 (A2780) 
20.4 (Bel-7402), 19.1 (BGC-823)
18.8 (HCT-8) 
3-bromo-4,5-dihydroxyphenylethanol sulfate [16] 
2.18  14.5 (A549), >16.9 (A2780) 
13.5 (Bel-7402), 15.1 (BGC-823)
12.1 (HCT-8) 
3-bromo-2-(2,3-dibromo-4,5-dihydroxybenzyl)-4,5- 
dihydroxyphenyethanol sulfate [16] 
Notes: unit for IC50 is µM, unless labeled as µg/mL. 
In another study, cytotoxicity of BPs (compounds 2.11,  2.12, and 2.13) from the red algae 
Polysiphonia lanosa was evaluated and some derivatives were synthesized. Compounds 2.11, 2.12, 
and  2.13 show obvious cytotoxicity against DLD-1 and HCT-116 cell lines with IC50 ranging  
from 1.32 to 14.6 µM. The most active compound is the synthetic compound 2.14 
(2,5-dibromo-3,4-dihydroxybenzyl n-propyl ether), which could significantly inhibit the proliferation 
of DLD-1 and HCT-116 cell lines (IC50 = 1.72 and 0.08 µM, respectively), and arrest the cell cycle of 
DLD-1 cells [69]. The preliminary SAR investigation considers that the activity is largely influenced 
by the number and position of bromine substituent, as well as the number of phenolic groups and side 
chains [69]. 
The phenylethanol and the phenylethanol sulfate BPs (2.15–2.18) show moderate cytotoxicity 
against several human cancer cell lines including HCT-8, Bel-7402, BGC-823, A549, and A2780 [16]. 
Comparing the IC50 values of 2.15 with that of 2.16, which is the sulfated 2.15, it seems that there is no 
obvious difference between their activities and the sulfate group is dispensable. However, the activity 
increases after bromination in 2.17, suggesting the importance of Br in the anticancer activity. To 
confirm the role of Br and sulfate group in their anticancer activity, further experiments are needed.   
Besides their promising cytotoxicty against various cancer cells, the selectivity of these BPs should 
be considered. This problem is also one of the main challenges for the current anticancer drugs. Some Mar. Drugs 2011, 9  
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BPs are also cytotoxic to normal cell lines, such as the human embryo lung fibroblasts 
(HELF) [33,77], with low selectivity, which may make their application in vivo difficult. Therefore, 
structural modification is needed to enhance their activity and selectivity. The anticancer activity of 
these BPs is largely confined to the in vitro level and the mechanism of action is still unclear. As 
reviewed in Section 2.1, BPs are considered to be free radical scavengers to prevent oxidative damage, 
which is a vital factor in carcinogenesis. Whether this antioxidant activity is responsible for their 
anticancer activity has yet to be established. More SAR studies and in vivo tests are needed to modify 
and evaluate these lead compounds. However, the anticancer activity of BPs mentioned above shows 
that BPs should be considered as a possible group of anticancer candidates, and these promising lead 
compounds may interest scientists in the organic synthetic and oncology area. 
2.3. Antimicrobial Activity 
The discovery of novel antibacterial agents has been going on for many years. However, the new 
drugs have not kept pace with the increasing drug resistance of bacteria. One of the major challenges is 
the limitation of screening libraries  [78,79]. Marine natural products may contribute to the 
improvement of these chemical libraries, and fortunately, various BPs from the marine algae have been 
reported to possess promising antibacterial activity. From the marine algae, Rhodomela confervoides, 
five BPs with antibacterial activity were isolated (3.1–3.5) (Scheme 3). Among these compounds, 
compound 3.5 has the most potent activity with the minimum inhibitory concentration (MIC) less than 
70 µg/mL (121 µM), while compounds 3.2, 3.3, and 3.4 are moderately active, when tested against eight 
strains of Gram positive and Gram negative bacteria [66] (see Table 3). Another study showed that, 
lanosol methyl ether (3.6), lanosol butenone (3.7) and rhodomelol (3.8), isolated from the New 
Zealand red algae Osmundaria colensoi, all exhibit antibacterial activity against the MC155 strain of 
Mycobacterium smegmatis (IC50 7.8, 26.2, and 28.1 µM, respectively) [67]. Lanosol ethyl ether (3.12) 
shows little antimicrobial activity, with mean bacteriostatic and fungistatic MIC of 0.27 ± 0.07 mg/mL 
(about 828 µM), and mean bacteriocidal and fungicidal MIC of 0.69 ± 0.15 mg/mL (about 2118 µM). 
Lanosol ethyl ether is thus a compound with good bacteriostatic and fungistatic activity. It has lower 
bactericidal and fungicidal activity but causes deformities in bacterial cells  [32]. All these results 
indicate that these BPs would be potential lead compounds for antibacterial drug design. However, the 
SAR results are difficult to compare since the bacteria strains are not the same in different experiments. 
In addition to the activity against bacteria, 3.3,  3.4, and 3.6 together with 3.9,  3.10, and 3.11  
(see Scheme 2) may be promising candidates for antifungal agents in crop protection. These BPs could 
reduce the appressorium formation by the fungus Magnaporthe grisea on rice plants, due to inhibition of 
the isocitrate lyase (ICL). ICL plays an important role in the glyoxylate cycle and is highly  
expressed during appressorium-mediated plant infection [68]. The preliminary SAR reveals that the 
diphenylmethane skeleton and bromine moiety of BPs are essential for the ICL inhibition [68].  
In subsequent experiments, series of BPs derivatives with different linkages between two phenol units 
and different bromination, were synthesized. The results reveal that these synthetic BPs derivatives also 
show strong inhibition against ICL and antimicrobial activity. The ICL enzyme inhibition activity 
increases with the increasing number of bromines in each series of molecules [80–82], suggesting the 
indispensible role of bromine in this enzyme inhibition. Mar. Drugs 2011, 9  
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Scheme 3. BPs with antimicrobial activity. 
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Table 3. Antimicrobial activity and names of compounds in Scheme 3. 
No. MIC/IC50 and Microbe  Names 
3.1  MIC 140 µg/mL (a,b,c)  3-bromo-4-(2,3-dibromo-4,5-dihydroxyphenyl) 
methyl-5-(hydroxymethyl)-1,2-benzenediol [66] 
3.2  MIC 70 µg/mL (a) 
MIC 140 µg/mL (b,c,d,e) 
3-bromo-4-(2,3-dibromo-4,5-dihydroxyphenyl) 
methyl-5-(ethoxymethyl)-1,2-benzenediol [66] 
3.3  MIC 70 µg/mL (a,b,c,d) 
IC50 2.1 ± 0.1 µM (ICL) 
3-bromo-4-(2,3-dibromo-4,5-dihydroxyphenyl) 
methyl-5-(methoxymethyl)-1,2-benzenediol [66,68] 
3.4  MIC 70 µg/mL (a–g) 
IC50 2.0 ± 0.1 µM (ICL) 
4,4′-methylenebis(5,6-dibromo-1,2-benzenediol) [66,68] 
3.5  MIC 70 µg/mL (a,b,f,g) 
MIC 140 µg/mL (d,e) 
MIC 35 µg/mL (c) 
Bis(2,3-dibromo-4,5-dihydroxybenzyl)ether [66] 
3.6  IC50 125.6 ± 8.6 µM (ICL) 
IC50 7.8 µM (h) 
Lanosol methyl ether [67,68] 
3.7  IC50 26.2 µM (h)  Lanosol butanone [67] 
3.8  IC50 28.1 µM (h)  Rhodomelol [67] 
3.9  IC50 116.1 ± 7.3 µM (ICL)  3,5-dibromo-4-hydroxyphenylethylamine [68] 
3.10  IC50 92.6 ± 5.8 µM (ICL)  2,3-dibromo-4,5-dihydroxybenzylalcohol [68] 
3.11  IC50 2.8 ± 0.2 µM (ICL)  2,2′,3-tribromo-3′,4,4′,5-tetrahydroxy-6′-hydroxymethyl
diphenylmethane [68] Mar. Drugs 2011, 9  
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Table 3. Cont. 
3.12  MIC 0.69 ± 0.15 µg/mL (i) 
MIC 0.27 ± 0.07 µg/mL (j) 
Lanosol ethyl ether [32] 
3.13  IC50 27 ± 6.3 µM (IHNV) 
22.0 ± 0.6 µM (IPNV) 
3-bromo-4,5-dihydroxybenzyl methyl ether [83] 
3.14  IC50 45 ± 9.1 µM (IHNV) 
57.0 ± 10.6 µM (IPNV) 
3-bromo-4,5-dihydroxybenzaldehyde [83] 
3.15  IC50 3.02 µg/mL (HSV-1) 
0.91 µg/mL (AP
r HSV-1) 
1.41 µg/mL (TK
−HSV-1) 
2,3,6-tribromo-4,5-dihydroxybenzyl methyl ether [84] 
3.16  IC50 7.82 µg/mL (HSV-1) 
7.20 µg/mL (AP
r HSV-1) 
11.21 µg/mL (TK
−HSV-1) 
2,3,6-tribromo-4,5-dihydroxybenzylalcohol [84] 
3.17  IC50 4.11 µg/mL (HSV-1)  (2R)-2-(2,3,6-tribromo-4,5-dihydroxybenzyl)- 
cyclohexanone [84] 
Notes: a, Staphylcoccus aureus ATCC29213; b, Staphylcoccus aureus 02-60;  
c,  Staphylcoccus epidermidis ATCC12228; d, Staphylcoccus epidermidis 02-4;  
e,  Escherichia coli ATCC25922; f, Pseudomonas aeruginosa ATCC27853;  
g,  Pseudomonas aeruginosa 02-29, h, MC155 strain of Mycobacterium smegmatis;  
i, mean bacteriocidal and fungicidal MIC; j, mean bacteriostatic and fungistatic MIC. 
The latest research found that 3-bromo-4,5-dihydroxybenzyl methyl ether (3.13) and 
3-bromo-4,5-dihydroxybenzaldehyde (3.14), may be potential agents against fish pathogenic virus, 
infectious hematopoietic necrosis virus, and infectious pancreatic necrosis virus [83]. For the human 
herpetic infection, compounds 3.15–3.17 are considered as novel antiviral agents against wildtype 
herpes simplex type 1 (HSV-1), phosphonoacetic acid-resistant HSV-1 (AP
r HSV-1), and thymidine 
kinase deficient HSV-1 (TK
−HSV-1) strains.  IC50 values of 3.15 against these virus strains were 
reported as 3.02, 0.91, and 1.41 µg/mL, respectively. Oral administration (20 mg/kg) of 3.15 for  
6–10 days could significantly delay the appearance of skin lesions and suppress the number of virus 
particles in the brain and skin without being toxic in HSV-1 strain 7401H infected mice [84]. Therefore, 
these reports show that certain BPs could be developed as promising antiviral agents. 
An increasing number of BPs have been reported to exhibit antimicrobial activity. Many of them 
are highly brominated and share the same 3-bromo-4,5-dihydroxybenzyl unit (3.1–3.8,  3.10–3.12, 
3.13–3.17), indicating the importance of the bromination and the 3-bromo-4,5-dihydroxybenzyl unit in 
the molecules. However, further SAR studies and structural modification are necessary to develop a 
new antimicrobial agent. Besides, the mechanisms underlying their antimicrobial activity, their 
activities as well as their toxicity in vivo, also have yet to be investigated. The increasing number of 
antimicrobial BPs is promising to the development of new antimicrobial agents. 
2.4. Anti-Diabetic Activity 
Despite the wide range of current anti-diabetic drugs used clinically, a large number of type 2 
diabetes mellitus (T2DM) patients still suffer hyperglycemia and serious complications. Therefore, the 
therapeutic challenge of T2DM makes it necessary to discover new anti-diabetic agents. Mar. Drugs 2011, 9  
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Marine algae have been used for a long time as a remedy for diabetes in folk medicine  [85]. 
Recently, BPs isolated from marine algae have been reported to be potential anti-diabetic agents, 
acting as both PTP1B inhibitors and alpha-glucosidase inhibitors. PTP1B regulates the insulin 
signaling pathway and agents targeting it could be effective in the treatment of diabetes  [86]. 
Alpha-glucosidase is an enzyme that plays a central role in carbohydrate digestion and is a preferred 
target for anti-diabetic drugs. Bromophenol derivatives from red algae Rhodomela confervoides, 
4.1–4.4 (Scheme 4), which contain one or two 2,3-dibromo-4,5-dihydroxybenzyl unit and highly 
brominated, inhibit PTP1B activity (IC50 were 2.4, 1.7, 1.5, and 0.84 µM, respectively) and the  
R. confervoides extracts could decrease the blood glucose level in diabetic rats [70]. These studies 
indicate that the in vivo anti-hyperglycemic activity could be partially due to the PTP1B inhibition. 
Recently, three analogs of 4.4 have been synthesized and investigated [87]. 
Scheme 4. BPs with anti-diabetic activity. 
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Moreover, other studies suggest that 4.3 together with 4.5 to 4.11 (Scheme 4) may be a novel kind 
of α-glucosidase inhibitor [7,8,10,11]. The most potent α-glucosidase inhibitor in the present series of 
BPs is bis (2,3,6-tribromo-4,5-dihydroxybenzyl) ether (4.5), with an IC50 of 0.03 µM [8], while the 
weakest one is 2,4-dibromophenol (4.10), with an IC50 of 110.4 µM. We suppose that the degree of 
bromination in these molecules may have a close relationship with their α-glucosidase inhibition based Mar. Drugs 2011, 9  
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on the following: their IC50 values decrease with the increase of the bromine number in the molecules, 
for example, 3-bromo-4,5-dihydroxybenzyl alcohol (4.6) inhibits against α-glucosidase with IC50 of 
100 µM, when one more position is brominated (4.9), the IC50 value decreases to 89 µM, while fully 
brominated, like in 4.8, it is 11 µM (Table 4). The same phenomenon was observed in 4.3 and its 
corresponding compound 4.5, in 4.10 and its corresponding compound 4.11. In addition, it seems that 
the number of the phenyl units in the molecules also affect the enzyme inhibition activity, 4.3 and 4.5, 
which possess diphenyl unit are much more active than the compounds with one phenyl unit (4.6, 4.8, 4.9). 
The reason for these changes in activity remains unclear.   
Table 4. IC50 for enzyme inhibition and names of compounds in Scheme 4. 
No. IC50 Names 
4.1  2.4 
a 2,2′,3,3′-tetrabromo-4,4′,5,5′-tetra-hydroxydiphenyl methane [70] 
4.2  1.7 
a 3-bromo-4,5-bis(2,3-dibromo-4,5-dihydroxybenzyl)pyrocatechol [70] 
4.3  1.5 
a 
0.098 
b 
Bis(2,3-dibromo-4,5-dihydroxybenzyl)ether [8,10,11,70] 
4.4  0.84 
a 2,2′,3-tribromo-3′,4,4′,5-tetrahydroxy-6′-ethyloxy- 
methyldiphenylmethane [70] 
4.5  0.03 
b Bis(2,3,6-tribromo-4,5-dihydroxybenzyl)ether  [8] 
4.6  100 
b 3-bromo-4,5-dihydroxybenzylalcohol  [8] 
4.7  25 
b 4-bromo-2,3-dihydroxy-6-hydroxymethylphenyl 
2,5-dibromo-6-hydroxy-3-hydroxy-methylphenyl ether [11] 
4.8  11 
b 2,3,6-tribromo-4,5-dihydroxybenzylalcohol  [10] 
4.9  89 
b 2,3-dibromo-4,5-dihydroxybenzylalcohol [11] 
4.10  110.4 
b 2,4-dibromophenol  [7] 
4.11  60.3 
b 2,4,6-tribromophenol  [7] 
4.12  0.11 
c 2,2′,3,6,6′-pentabromo-3′,4,4′,5-tetrahydroxydibenzyl ether [31] 
4.13  0.4 
c Bis(2,3,6-tribromo-4,5-dihydroxyphenyl)methane  [31] 
4.14  0.4 
c 2,2′,3,5′,6-pentabromo-3′,4,4′,5-tetrahydroxydiphenylmethane [31] 
4.15  1.15 
c 2,3,6-tribromo-4,5-dihydroxymethylbenzene  [31] 
4.16  0.25 
c 2,3,6-tribromo-4,5-dihydroxybenzaldehyde  [31] 
Notes: 
a IC50 (µM) for PTP1B inhibition; 
b IC50 (µM) for α-glucosidase inhibition;  
c IC50 (µg/mL) for aldose reductase inhibition. 
Besides inhibition against PTP1B and α-glucosidase, some BPs also inhibit the aldose reductase. 
Aldose reductase is the first enzyme of the polyol pathway, which is responsible for fructose formation 
from glucose and plays an important role in the development of degenerative complications of 
diabetes [88]. For example, BPs from the red algae Symphyocladia latiuscula 4.12–4.16 (Scheme 4), 
are reported to have aldose reductase inhibitory activity and could be used in the treatment of 
complications of diabetes, such as eye and nerve damage in T2DM patients [31].   
BPs with strong alpha-glucosidase inhibition activity are being synthesized in our lab to evaluate 
their hypoglycemic activity in vivo, and we find that besides its antibacterial and antitumor activities, 
the alpha-glucosidase inhibitor, bis (2,3-dibromo-4,5-dihydroxybenzyl) ether (4.3) could also 
significantly alleviate the postprandial blood glucose level both in normal and diabetic animals [89]. 
Considering that alpha-glucosidase and PTP1B also play an important role in cancer, it seems useful to Mar. Drugs 2011, 9  
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investigate if the alpha-glucosidase and PTP1B inhibition of BPs is relevant for their anticancer 
activity. PTP1B and alpha-glucosidase inhibition, together with the antioxidant activity mentioned in 
Section 2.1, suggest that BPs may be promising candidates for development of anti-diabetic agents.   
2.5. Other Bioactivities 
Besides the activities mentioned above, other bioactivities were also reported, including the 
inhibition against thrombin, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, and 
phospholipase A2.  
Thrombin is the ultimate proteinase of the coagulation cascade, which makes it an attractive  
target for the treatment of a variety of cardiovascular diseases. A bromophenol derivative 
(+)-3-(2,3-dibromo-4,5-dihydroxyphenyl)-4-bromo-5,6-dihydroxy-1,3-dihydro-isobenzofuran (5.1) 
(Scheme 5), isolated from the brown algae Leathesia nana exhibits significant thrombin inhibitory 
activity both in vitro and in vivo [38,90]. 
Scheme 5. BPs with other activities. 
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Rawsonol (5.2), a novel brominated diphenyl methane derivative, which is isolated from the green 
algae Avrainvillea rawsoni, inhibits the activity of HMG-CoA reductase [41]. HMG-CoA reductase is 
the key enzyme in cholesterol biosynthesis and the target of the widely available cholesterol-lowering 
drugs. The observed inhibition therefore indicates the potential use of diphenylmethane derivatives in 
lowering of cholesterol levels. 
Moreover, anti-inflammatory effects were observed for Vidalols A (5.3) and B (5.4), which are 
obtained from the red alga Vidalia obtusaloba. The two compounds could clearly reduce the edema in 
phorbol ester induced swelling of the mouse ear, via inhibition of the arachidonic acid metabolic Mar. Drugs 2011, 9  
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pathway enzyme phospholipase A2 (bee venom PLA2) [29]. Therefore, Vidalols A and B could be 
possible lead compounds for the design of anti-inflammatory agents. 
However, not all the BPs show beneficial health effects. Some natural BPs such as 
2,4-dibromophenol (5.5) and 2,4,6-tribromophenol (5.6), used as flame retardants and fungicides,  
are suspected to show negative impact on human and animal health  [91,92]. For instance, 5.5 is 
revealed to bind to the estrogen receptor and act as an endocrine disruptor [91], while 5.6 inhibits  
cell proliferation and induces neuronal cell differentiation in human neuroblastoma cell line 
(SH-SY5Y) [93].  Another study reveals that 5.5 and 5.6 disturb cellular Ca
2+ signaling in 
neuroendocrine cells (PC12) [94]. 5.6 tested in vivo is reported to interfere with the steroidogenic 
pathway, reproduction, and embryo development in zebrafish [95,96]. Besides 5.6, other brominated 
indoles and phenols are also reported to be toxic (lethal and malformations) to the zebrafish 
embryos [97]. These results indicate the possible toxicity of 5.5 and 5.6 both in vitro and in vivo. 
Therefore, their possible toxicity for all life forms should be kept in mind.   
3. Conclusions  
The BPs obtained from macroalgae enlarge the chemical library and improve the opportunity to 
discover new pharmaceutical agents, and interesting novel BPs will still be found in the future. One 
interesting point is that no BPs were reported in microalgae. The exact mechanism is still unknown 
underlying the distribution of BPs. Further study is needed to address if BPs could be isolated from 
microalgae. Intensive efforts and obvious progress have been made in recent years and provide evidence 
that BPs exhibit diverse biological activities, including antioxidant, antibacterial, anticancer, and 
anti-diabetic activity. SAR study reveals that some core structure or substituents may play a critical 
role for the biological activity of BPs. In some cases like antioxidant effect, the presence of bromine 
substituents seems of little importance, whereas the number of hydroxyl groups is clearly important. The 
mutual orientations of the hydroxyl groups are also a useful character for antioxidant activity. Although 
para-substitution of hydroxyl groups is considered the most effective mutual orientations, this kind of 
mutual orientation was not found in BPs. Ortho-substitution is also a useful character for antioxidant 
activity. In both cases quinone formation is easy. In addition, conjugation connected to substituents such 
as acetyl, nitro or phenyl is important for antioxidant activity. Bromines play a key role in the 
anti-diabetic activity and cytotoxicity. With regard to toxicity towards cancer cells, the number of 
bromines plays a role and alkylation of phenol groups lower the activity. It should also be noted that the 
activity towards diverse cell lines differs. However, too few derivatives are available to draw a 
conclusion about the importance of the relative positions of substituents. A structure such as that found 
in Figure 1, or a derivative thereof, seems to be common for the biological effects. The mode of action 
of BPs has not well been documented, but it should be kept in mind that bromine may act as a halogen 
bond donor as seen in 4,5,6,7-tetrabromobenzotriazole [98].  
Unfortunately, so far it has proved difficult to identify a selective, safe and effective new drug from 
these BPs. One of the major challenges in developing potential therapeutic agents from BPs is the 
limited amount of BPs in these marine algae, which hinder an immediate in vivo investigation. Another 
challenge seems to be that the present research mainly focuses on the isolation and characterization of 
BPs compounds, but pays less attention to the biological activities, the mechanisms underlying their Mar. Drugs 2011, 9  
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activities, and the structure–activity relationships. Therefore, more pharmaceutical chemistry including 
synthesis of compounds and in vivo studies are needed in order to develop novel agents. 
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